First Manhattan’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

First Manhattan’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,400	Closed	-$14K	–	1813
2022 Q3	$14K	Hold	6,400	–	–	﹤0.01%	1156
2022 Q2	$19K	Sell	6,400 -6,000	-48%	-$29.2K	﹤0.01%	1129
2022 Q1	$84K	Hold	12,400	–	–	﹤0.01%	914
2021 Q4	$103K	Hold	12,400	–	–	﹤0.01%	870
2021 Q3	$92K	Sell	12,400 -26,000	-68%	-$161K	﹤0.01%	877
2021 Q2	$261K	Hold	38,400	–	–	﹤0.01%	685
2021 Q1	$394K	Hold	38,400	–	–	﹤0.01%	581
2020 Q4	$268K	Sell	38,400 -5,600	-13%	-$43.6K	﹤0.01%	611
2020 Q3	$359K	Hold	44,000	–	–	﹤0.01%	556
2020 Q2	$303K	Hold	44,000	–	–	﹤0.01%	575
2020 Q1	$209K	Hold	44,000	–	–	﹤0.01%	607
2019 Q4	$384K	Hold	44,000	–	–	﹤0.01%	570
2019 Q3	$146K	Sell	44,000 -30,000	-41%	-$120K	﹤0.01%	745
2019 Q2	$366K	Hold	74,000	–	–	﹤0.01%	591
2019 Q1	$458K	Hold	74,000	–	–	﹤0.01%	575
2018 Q4	$249K	Hold	74,000	–	–	﹤0.01%	652
2018 Q3	$481K	Hold	74,000	–	–	﹤0.01%	583
2018 Q2	$566K	Sell	74,000 -4,000	-5%	-$57.7K	﹤0.01%	534
2018 Q1	$1.74M	Hold	78,000	–	–	0.01%	374
2017 Q4	$994K	Buy	78,000 +47,000	+152%	+$691K	0.01%	448
2017 Q3	$482K	Buy	+31,000	New	+$438K	﹤0.01%	545

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

First Manhattan's JNCE Position: Q4 2022 in Review

First Manhattan sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 6,400 shares — an estimated $14K sold.

First Manhattan first reported a position in JNCE in Q3 2017 and held it in 21 quarters. The position peaked at $1.74M in Q1 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

First Manhattan reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 6,400 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $14K.
First Manhattan first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 21 quarters.
First Manhattan's Jounce Therapeutics, Inc. Common Stock position peaked at $1.74M in Q1 2018.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.